Regeneron Pharmaceuticals holds the cleaner structural position, with growth as the main driver and valuation adding further support. Verisk Analytics still has the edge on profitability, which keeps the comparison from looking entirely one-sided. On the market side, Regeneron Pharmaceuticals is in better shape — its trend is intact while Verisk Analytics's trend has broken down. That puts structure and market broadly in agreement — Regeneron Pharmaceuticals's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
The clearest score difference appears in growth, while profitability still leans the other way.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
The clearest structural overlap shows up in margin trend and capital structure.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Regeneron Pharmaceuticals, Inc. and Verisk Analytics, Inc. look relatively close on structure, but the price setup still leans toward Regeneron Pharmaceuticals, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where REGN and VRSK each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The main growth separation is wide, driven by a meaningfully stronger expansion profile.
Profitability still favours Verisk Analytics, with a 12-point operating margin advantage keeping the comparison from looking fully resolved.
Growth is the clearest driver of the lead, with valuation adding further support — though profitability still provides a real counterweight.
Break down the REGN vs VRSK comparison across all dimensions with the full interactive tool.
Explore how REGN and VRSK each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.